Navigation Links
DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advisory Board
Date:6/3/2008

LA JOLLA, Calif., June 3 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, today announced that Herbert A. Fritsche, Ph.D., has joined DermTech's Scientific Advisory Board. Dr. Fritsche is Professor and Chief of Clinical Chemistry at M.D. Anderson Cancer Center and one of the world's experts in the development and validation of cancer diagnostics for early disease detection and in the fast-growing area of translational research, moving research into clinical practice.

"We are honored that Dr. Fritsche is joining DermTech's Scientific Advisory Board and we are delighted to welcome him to the company," said George Schwartz, CEO, DermTech. "Dr. Fritsche has been with M.D. Anderson for almost 40 years and is one of the pioneers of today's molecular diagnostic assays for cancer detection and predicting drug response. His expertise will clearly be a major asset to DermTech as we are moving forward at an accelerated pace to develop our first product for the non-invasive early detection of melanoma."

"I am very pleased to become a member of DermTech's SAB and assist the company as it continues to optimize its novel melanoma assay and develops additional diagnostics using its "tape stripping" technology for the early detection of disease," said Herbert A. Fritsche, Ph.D. "This is an exciting time in medicine - in the field of cancer, I predict that within 10 years and maybe less, no major treatment decisions will be made without first consulting a laboratory test. I am looking forward to applying my experience to what I believe will be the next-generation approach to improved cancer detection."

Dr. Fritsche's career at M.D. Anderson includes some of the earliest work in translational research including the development of blood and tissue tests for protein tumor markers (CEA, AFP, HCG, LDH, B2M, estrogen and progesterone receptors), more recently, tests for cir
'/>"/>

SOURCE DermTech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
2. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
3. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Abt Associates Names Richard Small Vice President and Chief Financial Officer
6. Premier Research Names Anthony Faragasso, MD as Executive Director and Global Head of Medical Management and Safety
7. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
8. Gene Network Sciences Names New CSO and Announces New Scientific Advisory Board
9. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
10. Codexis Names David Anton VP Bioindustrials R&D
11. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... China, Feb. 12 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC ... company with its principal operations,in the People,s Republic of ... call at 9:00 a.m. Eastern on Tuesday, February 17, ... December 31, 2008 of,its fiscal year 2009. , ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... http://www.cordblood-america.com ) focused on bringing the life saving potential ... pleased to announce that between January 1, 2009, and ... approximately $1 million.The Company previously said in press releases ...
... (NYSE Alternext US: PTN) will announce its second quarter, ... 2009 before the open of the U.S. financial markets.Palatin ... webcast hosted by its executive management team on February ... of operations in greater detail and an update on ...
Cached Biology Technology:Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 2Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 3Cord Blood Announces $1 Million Reduction in Long Term Debt 2Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009 2
(Date:7/9/2014)... Cholinergic inhibitors and N-methyl-D-aspartate receptor antagonists can ... fail to affect irreversible cognitive dysfunction and ... brain. Amyloid beta peptide (Aβ) vaccines reduced ... disease (AD) transgenic mouse model, and significantly ... Cao and his team, First Affiliated Hospital ...
(Date:7/9/2014)... copy of its DNA, a fundamental step in the life ... in the human body. While scientists have had an idea ... enzymes that unzip the double-stranded DNA and create "daughter" copiesthey ... works. , Now, researchers at Rockefeller University have built the ... "replication fork"the point where DNA is split down the middle ...
(Date:7/8/2014)... is an increased risk of severe perineal tearing during childbirth ... delivery, suggests a new study published today (9 July) in ... (BJOG). , This study, investigates among women who have had ... delivery in subsequent pregnancies and the recurrence of severe perineal ... childbirth and in some women the tear may be more ...
Breaking Biology News(10 mins):Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4Mode of delivery following a perineal tear and recurrence rate in subsequent pregnancies 2
... carry out one of the most remarkable forms of feeding ... extending its stomach out of its mouth and over the ... The prey tissue is partially digested externally before the soup-like ... , The researchers at Queen Mary, University of London and ...
... of breast cancer, termed estrogen receptor positive or ER+, ... each year. Research by scientists at the HudsonAlpha ... Birmingham Comprehensive Cancer Center aims to provide physicians a ... "Can we find something in the genome that correlates ...
... shape based on environment, fending off attackers or ... worked toward mimicking similar biological responses in non-living ... the medical arena. Now, researchers at ... biomimetic response using hydrogelsa material that constitutes most ...
Cached Biology News:Scientists uncover secrets of starfish's bizarre feeding mechanism 2HudsonAlpha and UAB researchers work to identify optimal treatments for ER+ breast cancer 2Light that moves and molds gels 2
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: